Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30930714 | 0.84 | POLB (0.50) | GAAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL28471319 | 0.83 | CES2 (0.61) | GAAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL6450415 | 0.82 | ALDH1A1 (0.70) | GAAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL298653 | 0.80 | GAA (0.67) | GAAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL29382881 | 0.80 | GAA (0.67) | GAAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL2222719 | 0.78 | GAA (0.64) | GAAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL21779849 | 0.78 | GAA (0.64) | GAAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL255025 | 0.78 | GAA (1.00) | GAAMEN1KMT2ATDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28973500 | 0.78 | GAA (0.64) | GAAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL28190255 | 0.78 | GAA (0.64) | GAAMEN1KMT2ATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414346-A1 | AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-02-08 | — | — | EP | claimed |
| WO-2010112124-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-07 | — | — | WO | claimed |
| CN-110437205-A | Pyridine alkenyl piperidine derivative and application thereof | GUANGDONG HEC PHARMACEUTICAL | 2019-11-12 | — | — | CN | disclosed |
| CN-110366550-A | Benzoisothiazole, isothiazolo [3,4-b ] pyridine, quinazoline, phthalazine, pyrido [2,3-d ] pyridazine and pyrido [2,3-d ] pyrimidine derivatives as KRAS G12C inhibitors for the treatment of lung, pancreatic or colorectal cancer | 美国安进公司 | 2019-10-22 | — | — | CN | disclosed |
| CN-110272425-A | Pyridine acyl octahydro pyrrolo- [3,4-c] azole derivatives and application thereof | 广东东阳光药业有限公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-110123820-A | Arginase inhibitor and its application method | 阿斯利康公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-104857005-B | Arginase inhibitor and its application method | 阿斯利康公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-109180670-A | Imino group thiadiazine dioxide derivative and application thereof | 广东东阳光药业有限公司 | 2019-01-11 | — | — | CN | disclosed |
| EP-3191112-A2 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED, S.L. (ES) | 2017-07-19 | — | — | EP | disclosed |
| CN-103687860-B | As P2X7Heterocyclic amide derivatives of receptor antagonists | 埃科特莱茵药品有限公司 | 2016-06-08 | — | — | CN | disclosed |
| WO-2016038040-A2 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED, S.L. (ES) | 2016-03-17 | — | — | WO | disclosed |
| CN-104718188-A | N-substituted benzamides and their use in the treatment of pain | GENENTECH INC | 2015-06-17 | — | — | CN | disclosed |
| CN-104487433-A | Triazolone compounds as mpges-1 inhibitors | GLENMARK PHARMACEUTICALS SA | 2015-04-01 | — | — | CN | disclosed |
| CN-104059058-A | Compositions and methods for controlling nematodes | MONSANTO TECHNOLOGY LLC | 2014-09-24 | — | — | CN | disclosed |
| CN-104054719-A | Compositions And Methods For Controlling Nematodes | MONSANTO TECHNOLOGY LLC | 2014-09-24 | — | — | CN | disclosed |
| EP-2519522-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2009-07-23 | — | — | US | disclosed |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | GAA 2424/4885MEN1 1121/4885KMT2A 823/4885 |
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | GAA 1404/4885MEN1 4656/4885KMT2A 3024/4885 |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | GAA 2538/4885MEN1 239/4885KMT2A 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.